Management of thrombocytopenia in bone marrow failure: A review

Journal of Palliative Medicine

Volumn 10, Issue 1, 2007, Pages 236-244

  Salacz, Michael E ^a   Lankiewicz, Michael W ^b   Weissman, David E ^c  

^a Specialists in Cancer Care   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ALLOIMMUNIZATION; ANEMIA; APLASTIC ANEMIA; BLEEDING; BONE MARROW DEPRESSION; BREAST CANCER; CAREGIVER; CHRONIC LEUKEMIA; CYTOPENIA; DISEASE COURSE; FEVER; HEMATOLOGIC DISEASE; HOSPICE CARE; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PALLIATIVE THERAPY; PATIENT MONITORING; PROSTATE CANCER; REVIEW; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTIFIBRINOLYTIC AGENTS; BONE MARROW DISEASES; CHRONIC DISEASE; HUMANS; PALLIATIVE CARE; PATIENT CARE MANAGEMENT; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 33846925335     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.0126     Document Type: Review

References (29)

1. Erslev AJ: Anemia associated with marrow infiltration. In: Beutler E, Lichtman MS, Beutler E, Kipps TJ Williams WJ (eds): Williams Hematology, 6th ed. New York: McGraw-Hill, 2001, pp. 477-480.
2. Dale DC: Neutropenia and neutrophilia. Beutler E, Lichtman MS, Beutler E, Kipps TJ Williams WJ (eds): Williams Hematology, 6th ed. New York: McGraw-Hill, 2001, pp. 823-834.
3. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA: Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications. Leuk Res 1999;23:953-959.
4. Latagliata R, Alimena G, Carmosino I, Breccia M, Borza PA, Bongarzoni V, Copia C, Spadea A, Pinazzi B, Frattarelli N, Ferrara F, Petti MC, Mandelli F: Conservative treatment for patients wver 80 years with acute myelogenous leukemia. Am J Hematol 2002;71:256-259.
5. Stalfelt AM, Brodin H, Pettersson S, Eklof A: The final phase in acute myeloid leukaemia (AML): A study on bleeding, infection and pain. Leuk Res 2003;27:481-488.
6. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;18:905-909.
7. Han T, Stutzman L, Cohen E, Kim U: Effect of platelet transfusion on hemorrhage in patients with acute leukemia. Cancer 1966;19:1937-1942.
8. Murphy S, Litwin S, Herring LM, Koch P, Remischovsky J, Donaldson MH, Evans AE, Gardner FH: Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982;12:347-356.
9. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH; American Society of Clinical Oncology. Platelet Transfusion for Patients with Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-1538.
10. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338:1223-1226.
11. 9/Liter trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601-3606.
12. Sagmeister M, Oec L, Gmur J: A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999;93:3124-3126.
13. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S: Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002;16:34-45.
14. British Society for Haematology: Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10-23.
15. Wandt H, Frank M, Schaefer-Eckart K, Wilhelm M: Routine prophylactic platelet transfusions are not necessary in patients with acute myeloid leukemia(A therapeutic transfusion strategy is safe and cost effective. Blood 2005;106:Abstract 428.
16. Tinmouth AT, Freedman J: Prophylactic platelet transfusions: Which dose Is the best dose? A review of the literature. Transfusion Med Rev 2003;17:181-193.
17. Coluccio E, Rebulla P: Platelet transfusion. Haematologica 2002;87:1121-1122.
18. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA: Platelet transfusions: Utilization and associated costs in a tertiary care hospital. Am J Hematol 2000;64:251-256.
19. Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA; College of American Pathologists. Transfusion Medicine Resource Committee. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003;127:409-414.
20. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1977;337:1861-1869.
21. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
22. Chiu J, Ketchum LH, Reid TJ: Transfusion-sparing hemostatic agents. Curr Opin Hematol 2002;9:544-550.
23. Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F: Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies, Haematologica 1997;82:584-587.
24. Bartholomew R, Salgia R, Bell WR: Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 1989;149:1959-1961.
25. Gardner FH, Helmer RE: Aminocaproic acid use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980;243:35-37.
26. Benson K, Fields K, Hiemenz J, et al; The platelet refractory bone marrow transplant patient: prophylaxis and treatment of bleeding, Semin Oncol, 1993; 20 (5 suppl 6): 102-9.
27. Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders, Blood 2004;10:3858-3864.
28. Goodnough LT: Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004;41:25-29.
29. Vidarsson B, Onundarson PT: Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634-635.